Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,810
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,810 facts checked against source5,217 source documents archived
Work with this data → vianewsagency.com

PCI BIOTECH HOLD Stock Over 13% Down So Far On Monday

Loading stream...

(VIANEWS) - Shares of PCI BIOTECH HOLD (Oslo Børs Benchmark Index_GI: PCIB.OL) slid by a staggering 13.25% to kr1.80 at 11:44 EST on Monday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is jumping 0.86% to kr1,214.91, following the last session's upward trend. This seems, at the moment, a somewhat positive trend exchanging session today.

PCI BIOTECH HOLD's last close was kr2.08, 65.18% below its 52-week high of kr5.96.

About PCI BIOTECH HOLD

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-1.54.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -64.36%.

Volatility

PCI BIOTECH HOLD's last week, last month's, and last quarter's current intraday variation average was 0.97%, 0.37%, and 3.77%.

PCI BIOTECH HOLD's highest amplitude of average volatility was 4.64% (last week), 3.17% (last month), and 3.77% (last quarter).

Volume

Today's last reported volume for PCI BIOTECH HOLD is 78976 which is 40.72% below its average volume of 133238.

Moving Average

PCI BIOTECH HOLD's value is way below its 50-day moving average of kr2.08 and way below its 200-day moving average of kr2.38.

More news about PCI BIOTECH HOLD (PCIB.OL).